Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
February 04, 2021 07:10 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
Endocrine Testing Market To Reach USD 15.09 Billion By 2026 | Reports And Data
December 02, 2019 10:14 ET
|
Reports and Data
New York, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Increasing incidence of diabetes, thyroid, sedentary lifestyle, increasing government support, growing healthcare awareness and obesity are key factors...
Earth Science Tech, Inc. (ETST) Issues Update on CBD Patents and Reacts to DEA’s Shift on CBD
October 03, 2018 08:00 ET
|
Earth Science Tech, Inc.
DORAL, Florida, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and...
Earth Science Tech, Inc. (ETST) Receives Updated Coverage and $3.60 Price Target from SeeThruEquity
September 27, 2018 08:00 ET
|
Earth Science Tech, Inc.
DORAL, Florida, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTCQB: ETST) (“ETST" or the “Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and...
Relora(R) Included as Part of Flat Belly Plan
February 07, 2013 16:23 ET
|
Relora(R)
SALINAS, Calif., Feb. 7, 2013 (GLOBE NEWSWIRE) -- The nation's leading health and wellness television program has, for the second time, featured Relora and its importance in the fight against belly...